Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092334 | 0.80 | HRH3 (0.56) | HTR2CPRMT6GRM2PPARAGRIN2B | |
| SCHEMBL16894251 | 0.80 | MAOB (0.53) | FFAR4 | |
| Hydrochloric Acid SCHEMBL2803821 | 0.79 | HRH3 (0.54) | HTR2CPRMT6GRM2 | |
| SCHEMBL106741 | 0.78 | HTR2C (0.54) | HTR2CGRIN2B | |
| Iodide SCHEMBL29203661 | 0.76 | HTR2C (0.52) | HTR2CGRIN2B | |
| Bromide SCHEMBL29203657 | 0.76 | HTR2C (0.52) | HTR2CGRIN2B | |
| Hydrochloric Acid SCHEMBL13268897 | 0.76 | MAOB (0.53) | HTR2CGRIN2B | |
| SCHEMBL999605 | 0.76 | FFAR4 (0.45) | FFAR4FFAR1HTR2CABL1CYP2C9 | |
| SCHEMBL10075879 | 0.76 | ABAT (0.52) | BACE1 | |
| SCHEMBL999155 | 0.75 | TRPV3 (0.49) | FFAR4FFAR1ABL1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454240-A1 | GLYCINE TRANSPORTER INHIBITORS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | FFAR4 3234/4885FFAR1 2512/4885HTR2C 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.